Viking Therapeutics
VKTX
18 hedge funds and large institutions have $3.85M invested in Viking Therapeutics in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
128% more capital invested
Capital invested by funds: $1.69M → $3.85M (+$2.16M)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more funds holding
Funds holding: 12 → 18 (+6)
1.63% more ownership
Funds ownership: 5.67% → 7.3% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
+$554K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$329K |
| 3 |
Renaissance Technologies
New York
|
+$118K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$64.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$58.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$525K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$11.4K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$2K |
VKTX Hedge Fund Activity: Q3 2017 in Review
18 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2017, worth a combined $3.85M — up 128% from $1.69M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VKTX positions and 2 closed out — a net gain of 7 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Ascend Capital, opening a new position worth an estimated $554K. The largest seller was Sabby Management, exiting entirely with an estimated $525K sold.
- 18 institutional investors held Viking Therapeutics (VKTX) as of Q3 2017, up from 12 in Q2 2017.
- Funds reported $3.85M of Viking Therapeutics stock for Q3 2017, up 128% quarter-over-quarter.
- 9 funds opened new Viking Therapeutics positions in Q3 2017 and 2 closed out, a net change of +7 holders.
- The largest Viking Therapeutics buyer in Q3 2017 was Ascend Capital, an estimated $554K added.
- The largest Viking Therapeutics seller in Q3 2017 was Sabby Management, an estimated $525K sold.
Based on aggregated 13F filings for Q3 2017.